Computational Drug Repurposing Approach to Identify Novel Inhibitors of ILK Protein for Treatment of Esophageal Squamous Cell Carcinoma

Figure 5

Evaluation of the anticancer activity of two screening compounds. (a, b) IC50 values of nilotinib and teniposide in ESCC cells. TE-1 and KYSE150 cells were treated with different concentrations of two drugs for 48 hours. The cell viability was assessed by CCK8 assay, and IC50 values were calculated. (c, d) Cell viability and LDH release of ESCC cells (TE-1 and KYSE150) detected using the CCK8 and LDH assay after treatment of nilotinib and teniposide conditioned medium or control medium (^∗∗∗p < 0.001).

(a)

(b)

(c)

(d)